3月24日，香雪制药（300147.SZ）公告称，公司及相关当事人收到中国证监会广东监管局的《行政 处罚事先告知书》。香雪制药及王永辉、卢锋、陈炳华、黄滨、徐力、郝世明等人拟被罚合计2075万 元，其中王永辉违法情节严重，被采取5年证券市场禁入措施。 同日，香雪制药还发布了另外一份公告称，根据《深圳证券交易所创业板股票上市规则》第9.4条 规定，公司股票交易将被实施其他风险警示。公司股票自2025年3月25日（星期二）被实施其他风险警 示，股票简称由"香雪制药"变更为"ST香雪"。 公告显示，2019年12月，香雪制药位于广州生物岛上5栋别墅被相关政府部门拆除，香雪制药未按 规定确认拆除别墅产生的在建工程损失，导致2019年年度报告虚增利润5383.25万元，占当期披露利润 总额的45.98%，2019年年度报告存在虚假记载。 此外，2016年至2020年，香雪制药以购买信托理财、中药材合作经营等名义支出款项，并最终划转 至控股股东广州市昆仑投资有限公司等关联方，用于关联方偿还借款、收购股权等。2018年至2020年， 香雪制药代关联方广州香岚健康产业有限公司支付香岚官洲酒店工程款。 香雪制药及相关人员拟被罚 ...

早报消费贷提额延期 央行再提择机降准降息 | | | | | 3月24日 交易提示 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 项目 | 代码简称 | 发行价 | 市盈率 | 参考行业 市盈率 | 参考行业 | 总市值 | 主营 | | 新股申购 | 首航新能 301658 | 11. 80 | 15. 88 | 19. 26 | 电气机械和 器材制造业 | 43.79亿 | 从事新能源电力设备研 发、生产、销售及服务 | | | | | | | | | 0 | | 新股上市 | 矽电股份 301629 | 52. 28 | 26. 23 | 29. 67 | 专用设备制 造业 | 21.82亿 | 半导体专用设备的研发 、生产和销售。 | 宏观新闻 1、李强上周五主持召开国务院常务会议，研究建立健全涉企收费长效监管机制有关举措。会议指出， 要健全涉企收费目录清单制度，将所有收费项目均纳入清单并对社会公开，明确服务内容、服务标准、 收费额度，清单之外一律不得收费，依法依规对存量涉企收费政策进行清理。 2、中共中央政治局委员、国务院副总 ...

Core Viewpoint - Several A-share companies are facing risk warnings due to violations related to false disclosures in their financial reports, leading to temporary trading suspensions and changes in stock designations to "ST" [1][4][7][11]. Group 1: Company Specifics - Xiangxue Pharmaceutical will be designated as "ST Xiangxue" after receiving a notice from the China Securities Regulatory Commission (CSRC) regarding false disclosures in its 2019 annual report, which included significant omissions related to related party non-operating fund occupation from 2016 to 2020 [4][6]. - Langyuan Co. will be designated as "ST Langyuan" following a similar notice from the Shandong Securities Regulatory Bureau, which identified false disclosures in its 2019 annual report, including inflated revenue and profits due to non-commercial contracts [8][9]. - Lianchuang Co. will also be designated as "ST Lianchuang" after receiving a notice indicating false disclosures in multiple reports from 2017 to 2019, particularly related to the acquisition of Shanghai Aotou and inflated financial figures [12][14]. Group 2: Regulatory Actions - The CSRC plans to impose penalties on Xiangxue Pharmaceutical, including a warning and a fine of 6 million yuan, along with individual fines for responsible parties [5][6]. - Langyuan Co. faces a proposed fine of 5 million yuan and individual penalties for executives, with significant market bans for key individuals [10]. - Lianchuang Co. is expected to receive a warning and a fine of 600,000 yuan, with severe penalties for responsible executives, including lifetime market bans for some [14].

Key Points - The article discusses significant developments in China's economic and financial landscape, including policy changes and corporate announcements that may impact investment opportunities and market dynamics. Group 1: Economic Policies and Developments - The China Development Forum 2025 will be held in Beijing from March 23 to 24, focusing on high-quality development and consumer expansion strategies [2][5]. - The People's Bank of China held a monetary policy meeting on March 18, suggesting an increase in monetary policy adjustment intensity and the potential for interest rate cuts to stabilize the capital market [5]. - A new notification from the National Financial Supervision Administration allows for an increase in personal consumption loan limits, aiming to boost consumer spending [6]. Group 2: Corporate Announcements - Yulong Co. announced a proposal to voluntarily terminate its stock listing, becoming the first A-share company to do so in 2025 [3][10]. - Meituan reported a revenue of 337.6 billion yuan for 2024, a 22% increase year-on-year, with adjusted net profit rising by 88% to 43.77 billion yuan [12]. - Lier Chemical announced plans to acquire control of Shandong Huimeng [13]. Group 3: Market Reactions and Trends - The launch of the 2025 National Home Appliance Consumption Season aims to stimulate consumer demand through various promotional activities [8]. - The stock of Yulong Co. will resume trading on March 24 after the announcement of its voluntary delisting proposal [11]. - The China Securities Regulatory Commission is intensifying efforts to build a transparent and resilient capital market, emphasizing strict enforcement against securities violations [7].

Key Points - The article emphasizes the Chinese government's commitment to implementing proactive macro policies to support economic stability and growth, including potential new policies if necessary [2] - The article highlights the importance of enhancing the business environment for various enterprises through economic reforms and addressing bottlenecks in economic circulation [2] - The article discusses the upcoming significant events in the global market, including earnings reports from major companies and important economic data releases [4] Macro - Premier Li Qiang met with U.S. senators, stating that trade wars yield no winners and emphasizing the need for cooperation to address trade imbalances [6] - Vice Premier He Lifeng welcomed multinational companies to invest in China, highlighting the resilience and potential of the Chinese economy [6] - The government plans to deepen supply-side structural reforms and regulate competition to promote high-quality development [6] Domestic Stock Market - CITIC Securities identified two critical time points for the market: the first in early April when external risks are expected to materialize, and the second mid-year when U.S. economic and policy cycles may align with China's [9] - The "Leading Enterprise" action plan in Guangzhou aims to enhance the integration of industry and capital, promoting more competitive companies to go public [9] - The report notes a significant increase in new account openings at several securities firms, indicating growing market participation [10] Financial - A surge in the number of funds focusing on free cash flow indicates a market trend towards financial health metrics, driven by demand and policy direction [14] - The head of the Industrial and Commercial Bank of China emphasized the shift from a capital-centric to a technology-centric financial service model [14] Real Estate - Suggestions were made to stabilize asset prices and improve income levels to boost consumer spending, particularly in real estate and equity markets [17] Industry - XPeng Motors' chairman discussed the future of high-level autonomous driving technology, predicting significant advancements in the coming years [19] - The Henan province announced plans for extensive 5G infrastructure development, aiming for over 270,000 5G base stations in the next three years [19] Overseas - The WTO Director-General highlighted the U.S. as a major beneficiary of global trade, countering claims of trade disadvantages [21] - The UK government plans to invest £600 million to address skill shortages in the construction sector, crucial for housing development [22] International Stock Market - SpaceX aims to achieve a weekly launch frequency for its Starship within a year, enhancing its operational capabilities [23] Commodity - The China Iron and Steel Association noted that supply-demand imbalances are a key issue in the industry, advocating for the closure of new production capacity [26] - Methanol port inventories have decreased, indicating a market shift towards destocking [26] - BHP's CEO projected a significant copper supply gap in the next decade, emphasizing the need for substantial investment in mining [26] Bonds - The government plans to issue long-term special bonds to support various initiatives, with a focus on local government debt management [28] - The AI and robotics sectors are identified as key drivers of market growth, with expectations for increased investment opportunities [28]

Core Viewpoint - Xiangxue Pharmaceutical has been penalized for information disclosure violations, leading to a warning and fines for its actual controller, Wang Yonghui, and other executives, while the company's stock has been marked with risk warnings due to false financial reporting [2][6]. Summary by Sections Company Penalties and Stock Status - On March 23, Xiangxue Pharmaceutical announced that Wang Yonghui received a warning and a fine of 10 million yuan, with several others also penalized. The company's stock will be marked with risk warnings, changing its name to "ST Xiangxue" while retaining the stock code "300147" [2]. - The stock will be suspended for one day starting March 24, 2025, and will resume trading on March 25, 2025 [2]. Violations and Financial Misreporting - The company was found to have false records in its 2019 annual report, which inflated profits by 53.83 million yuan, accounting for 45.98% of the total reported profit for that year [3]. - From 2016 to 2020, Xiangxue Pharmaceutical failed to disclose significant non-operating fund occupations involving related parties, with amounts of 585 million yuan, 845 million yuan, 1.408 billion yuan, 657 million yuan, and 1.357 billion yuan respectively [4]. Related Party Transactions - The company engaged in transactions that resulted in non-operating fund occupations, with undisclosed amounts in annual reports from 2016 to 2019, only revealing 1.262 billion yuan in the 2020 report [4][5]. - The undisclosed fund occupations represented significant percentages of the company's net assets, ranging from 2.22% to 38.79% across the years [4][5]. Management Accountability - Wang Yonghui was identified as the organizer of the fund occupation activities, leading to penalties for him and other executives, with fines ranging from 150,000 to 2 million yuan [6].

Investment Rating - The industry investment rating is maintained at "Overweight" [3][9]. Core Views - The market performance of the Chinese medicine sector showed a slight increase of 0.17% last week, while the overall pharmaceutical sector rebounded [2][5]. - The report highlights the continuous expansion of grassroots traditional Chinese medicine coverage, which is expected to drive demand growth [3]. - The revival of centralized procurement for traditional Chinese medicine is noted, with eight products entering the proposed selection list [3]. Market Performance - The Chinese medicine sector's PE (ttm) is reported at 25.89X, with a slight increase of 0.05X week-on-week, and the PB (lf) remains stable at 2.24X [7]. - The relative performance of the Chinese medicine sector compared to the CSI 300 index shows a decline of 4% over the past month and 21% over the past year [5]. Investment Suggestions - The report suggests looking for investment opportunities amid price governance and consumption recovery, indicating a dual scenario of pressure and opportunity in 2025 [9]. - Key investment themes include price governance, consumption recovery, and state-owned enterprise reform, with a focus on companies with strong R&D capabilities and market share [10][11][12].

证券代码:300147 证券简称:香雪制药 公告编号:2024-065 广州市香雪制药股份有限公司 2024 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决议案的情况。 2、本次股东会采取现场投票与网络投票表决相结合的方式召开。 一、会议召开和出席情况 1、广州市香雪制药股份有限公司（以下简称"公司"）于 2024 年 12 月 14 日以公告形式发出《广州市香雪制药股份有限公司关于召开 2024 年第二次临时 股东会的通知》。 公司部分现任董事、监事、高级管理人员和公司聘请的见证律师等相关人士 出席了会议。北京大成（广州）律师事务所吕晖律师和张秀婷律师见证了本次股 东会并出具了法律意见书。 （2）现场会议出席情况 2、会议召开方式：本次股东会采取现场投票与网络投票表决相结合的方式。 3、会议召开日期和时间 现场会议召开日期和时间：2024 年 12 月 30 日（星期一）上午 10:00 网络投票日期和时间：2024 年 12 月 30 日。其中，通过深圳证券交易所交 易系统进行网络投票的时 ...

广州市香雪制药股份有限公司 前期会计差错更正专项说明的鉴证报告 德皓核字[2024]00000289 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified PublicAccountants(Limited Liability Partnership) 广州市香雪制药股份有限公司 前期会计差错更正专项说明的鉴证报告 目 录 页 次 一. 前期会计差错更正专项说明的鉴证报告 1-2 二. 广州市香雪制药股份有限公司前期会计差错 更正专项说明 1-12 前 期 会 计 差 错 更 正 专 项 说 明 的 鉴 证 报 告 德皓核字[2024] 00000289 号 广州市香雪制药股份有限公司全体股东： 我们接受委托，审核了后附的广州市香雪制药股份有限公司（以 下简称"香雪制药"）编制的《前期会计差错更正专项说明》。 一. 管理层的责任 根据《企业会计准则第 28 号——会计政策、会计估计变更和差 错更正》、中国证券监督管理委员会《公开发行证券的公司信息披露 编制规则第 19 号——财务信息的更正及相关披露》等相关 ...

广州市香雪制药股份有限公司 第二条 独立董事专门会议是指全部由公司独立董事参加的会议。 独立董事是指不在公司担任除董事外的任何其他职务，并与公司及其主要股 东、实际控制人不存在直接或间接利害关系，或其他可能妨碍其进行独立客观判 断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、证券交 易所业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与决策、 监督制衡、专业咨询作用，维护公司整体利益，保护中小股东合法权益。 第二章 议事规则及职责权限 第四条 公司根据需要召开独立董事专门会议，原则上应当于会议召开前三 天通知全体独立董事并提供相关资料和信息。经全体独立董事一致同意，可免除 前述通知期限要求。 第五条 在保证全体参会独立董事能够充分沟通并表达意见的前提下，独立 董事专门会议可以采取现场、通讯视频、电话或者其他方式召开。过半数独立董 事可以提议可召开临时会议。 独立董事专门会议工作细则 第一章 总 则 第一条 为进一步完 ...